Kairos Pharma, LTD. (NYSE: KAPA)

Sector: Healthcare Industry: Biotechnology CIK: 0001962011
Market Cap 9.63 Mn
P/B 1.26
P/E -1.90
P/S 0.00
ROIC (Qtr) -82.03
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Investment thesis

Bull case

  • Cash reserves of 5.58M provide robust 13.87x coverage of current liabilities 402000, indicating strong short-term solvency.
  • Cash position of 5.58M represents healthy 0.89x of working capital 6.25M, demonstrating strong operational liquidity.
  • Robust R&D investment of 1.77M at 0.46x of SG&A 3.83M demonstrates strong commitment to innovation and future growth.
  • Strong tangible asset base of 7.96M provides 78.08x coverage of intangibles 102000, indicating robust asset quality.
  • Tangible assets of 7.96M provide robust 19.81x coverage of current liabilities 402000, showing strong asset backing.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 1.77M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (4.16M) shows concerning coverage of stock compensation expenses of 436000, with a -9.54 ratio indicating potential earnings quality issues.
  • High financing cash flow of 6.52M relative to working capital of 6.25M, which is 1.04x suggests concerning dependence on external funding for operational needs.
  • Operating cash flow of (4.16M) is outpaced by equity issuance of 6.66M (-0.62 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 7.96M provide limited backing for working capital of 6.25M, which is 1.27x, suggesting increased operational risk in market downturns.

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2024)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2024)

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.82 11.06
EV to Cash from Ops. EV/CFO -1.59 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -1.30 -13.49
EV to EBITDA EV/EBITDA -1.18 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -1.59 25.66
EV to Market Cap EV to Market Cap 0.69 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 1.26 20.59
Price to Earnings [P/E] P/E -1.90 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 73.30 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -87.62 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -182.84 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -87.62 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -84.68 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -24.00 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -99.42 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 13.87 3.92
Current Ratio Curr Ratio (Qtr) 16.56 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % 0.00 -17,888.70
EBIT Margin % EBIT Margin % 0.00 -18,246.34
EBT Margin % EBT Margin % 0.00 -19,108.08
Gross Margin % Gross Margin % 0.00 -10.30
Net Profit Margin % Net Profit Margin % 0.00 -19,056.96